News

The allowed claims cover the use of antibodies reactive with CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, of immune cells to deliver cancer and infectious

The two multi-center studies evaluated the safety and efficacy of Durezol 0.05% compared to placebo dosed twice a day (BID) and four times a day (QID) beginning 24

BioChemics has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal

The agreement is effective March 1, 2008 through 2010. It covers Magnevist in multiple presentations, including five, 10, 15 and 20mL single-dose vials, 50 and 100mL pharmacy bulk

The Phase II trial is a randomized, double blind, placebo controlled trial evaluating high risk geriatric patients following open heart surgery procedures. Patients in the treatment arm received

Kamada’s aerosolized Alpha-1 Antitrypsin product is currently undergoing Phase II clinical trials. David Tsur, CEO of Kamada, said: “This significant recognition grants Kamada various benefits such as research

The initial clinical development of Virulizin under the agreement will be in advanced pancreatic cancer. Under the terms of the agreement, GeneSense will be entitled to receive payments

The patent describes gene sequences, which have already been tested as HIV vaccine candidates in a Phase I clinical trial. Currently, the gene sequences are tested in a

The MITI IV is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic